New York State Teachers Retirement System Cuts Holdings in IQVIA Holdings Inc. (NYSE:IQV)

New York State Teachers Retirement System decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 5.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 166,940 shares of the medical research company’s stock after selling 9,518 shares during the period. New York State Teachers Retirement System’s holdings in IQVIA were worth $39,560,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the company. Canada Pension Plan Investment Board increased its position in shares of IQVIA by 6.6% during the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after acquiring an additional 211,653 shares during the last quarter. Lazard Asset Management LLC raised its stake in shares of IQVIA by 0.9% during the 1st quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock worth $825,416,000 after purchasing an additional 30,014 shares during the period. Farallon Capital Management LLC boosted its holdings in shares of IQVIA by 3.1% in the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after buying an additional 86,870 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in IQVIA by 3.8% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock valued at $634,927,000 after buying an additional 92,293 shares during the period. Finally, Capital Research Global Investors increased its holdings in IQVIA by 7.2% during the first quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock worth $540,882,000 after buying an additional 143,533 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQVIA stock opened at $216.04 on Thursday. The business has a 50-day simple moving average of $235.88 and a 200 day simple moving average of $230.06. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The stock has a market cap of $39.38 billion, a price-to-earnings ratio of 28.06, a PEG ratio of 2.09 and a beta of 1.49. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on IQV shares. Jefferies Financial Group downgraded shares of IQVIA from a “buy” rating to a “hold” rating and reduced their target price for the company from $266.00 to $242.00 in a research report on Wednesday, July 24th. Royal Bank of Canada initiated coverage on IQVIA in a report on Wednesday, September 4th. They set an “outperform” rating and a $275.00 price objective for the company. Morgan Stanley boosted their target price on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Robert W. Baird increased their price target on IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a research note on Friday, September 20th. Finally, UBS Group boosted their price objective on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $267.27.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.